|
시장보고서
상품코드
2039032
제네릭 항암 무균 주사제 시장 : 제품 종류별, 질환별, 유통 채널별, 지역별Generic Oncology Sterile Injectables Market, By Product Type, By Disease Indication, By Distribution Channel, By Geography |
||||||
제네릭 항암 무균 주사제 시장은 2026년에 358억 달러로 추정되며, 2033년까지 689억 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 9.8%로 성장할 것으로 전망됩니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2025년 | 시장 규모(2026년) | 358억 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) | 9.80% | 예측 금액(2033년) | 689억 달러 |
제네릭 항암 무균 주사제는 난소암, 유방암, 폐암 등 다양한 종류의 암 치료에 사용되고 있습니다. 제네릭 항암 무균 주사제는 브랜드 제품에 비해 상대적으로 저렴합니다. 치료비는 암 환자들에게 큰 관심사이며, 특히 인도, 브라질, 중국 등 신흥국에서 두드러지게 나타나고 있습니다. 따라서 이들 국가의 정부는 의약품 비용 절감과 접근성 향상을 위해 노력하고 있습니다. 예를 들어, 인도 국가 의약품 가격 규제국(NPPA)은 2017년 3월 일부 암 치료제의 가격을 86% 인하했습니다.
환자 수는 많지만 구매력이 상대적으로 낮은 이들 국가에서 제네릭 항암제 무균주사제는 큰 잠재력을 가지고 있습니다. 또한, 제품 특허 만료는 예측 기간 동안 제네릭 항암 무균 주사제 시장의 성장을 촉진할 것으로 예상됩니다. 바이오시밀러의 등장도 제네릭 항암제 무균 제품의 성장에 영향을 미치고 있습니다. 예를 들어, 'Journal of Generics and Biosimilars Initiative, 2017'에 따르면, 바이오시밀러는 2013년 이후 유럽과 2015년 이후 미국에서 각각 큰 점유율을 차지하고 있으며, 바이오시밀러의 점유율은 생물학적 제제 시장에서 큰 폭으로 증가할 것으로 예상됩니다. 이는 궁극적으로 제네릭 항암 무균주사제 시장의 성장을 촉진할 것으로 예상됩니다.
시장 역학
제네릭 항암 무균주사제 시장은 암 환자 수 증가에 따라 괄목할 만한 성장세를 보이고 있습니다. 예를 들어, 세계보건기구(WHO)에 따르면 2018년 전 세계적으로 약 1,810만 건의 신규 암 발생과 960만 명의 사망자가 보고되었습니다.
그러나 저소득 및 중저소득 국가에서 자궁경부암에 대한 대중의 인식 부족은 예측 기간 동안 제네릭 항암 무균주사제 시장의 성장을 저해할 것으로 예상됩니다. 자궁경부암은 저소득 및 중산층 가임기 여성에게 가장 흔한 암 중 하나입니다. 예를 들어, 국제암연구소(IARC)의 2013년 보고서에 따르면 자궁경부암은 주로 사하라 이남 아프리카의 저소득 국가에서 많이 발생합니다.
본 보고서의 주요 특징
- 이 보고서는 각 부문의 잠재적 수익 기회를 밝히고 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한, 시장 촉진 및 억제요인 및 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 업체들의 경쟁 전략 등에 대한 중요한 인사이트를 제공합니다.
- 세계 제네릭 항암제 무균 주사제 시장의 주요 기업 프로파일을 회사 개요, 제품 포트폴리오, 주요 특징, 재무 성과, 전략 등 다양한 매개 변수를 기반으로 작성되었습니다.
- 이 보고서의 인사이트를 통해 마케팅 담당자와 기업 경영진은 향후 제품 출시, 종류 업데이트, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있습니다.
- '세계 제네릭 항암제 무균 주사제 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 제네릭 항암 무균주사제 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 용이하게 할 수 있습니다.
목차
제1장 분석 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 제네릭 항암 무균 주사제 시장 : 제품 종류별(2021-2033년)
제5장 세계의 제네릭 항암 무균 주사제 시장 : 질환별(2021-2033년)
제6장 세계의 제네릭 항암 무균 주사제 시장 : 유통 채널별(2021-2033년)
제7장 세계의 제네릭 항암 무균 주사제 시장 : 지역별(2021-2033년)
제8장 경쟁 구도
제9장 섹션
KSM 26.06.04Generic Oncology Sterile Injectables Market is estimated to be valued at USD 35.8 Bn in 2026 and is expected to reach USD 68.9 Bn by 2033, growing at a compound annual growth rate (CAGR) of 9.8% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 35.8 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 9.80% | 2033 Value Projection: | USD 68.9 Bn |
Generic oncology sterile injectables are used for the treatment of various types of cancers such as ovarian, breast, and lung. Generic oncology sterile injectables products are relatively cheaper than branded counterparts. Treatment cost is a major concern for cancer patients, especially in emerging economies such as India, Brazil, and China. Therefore, governments of such countries are taking efforts to reduce cost of medications and increase its accessibility. For instance, the National Pharmaceutical Pricing Authority (NPPA) of India reduced the prices of few cancer products by 86% in March 2017.
Generic oncology sterile injectables have a huge potential in such countries, where patient population is high; however, spending power is relatively low. Furthermore, patent expiry of product is expected to fuel growth of the generic oncology sterile injectables market during the forecast period. The emergence of biosimilars have also impacted the growth of generics oncology sterile products. For instance, according to the Journal of Generics and Biosimilars Initiative, 2017, biosimilars have a major share in Europe and in the U.S. since 2013 and 2015, respectively, and the share of biosimilars is expected to increase significantly in the biologicals market. This is expected to eventually boost growth of the generic oncology sterile injectable market.
Market Dynamics
Generic oncology sterile injectables market is gaining significant traction due to rising prevalence of cancer cases. For instance, according to the World Health Organization, in 2018, around 18.1 Mn new cases of cancer and 9.6 Mn deaths were reported, globally.
However, lack of awareness amongst the people in low-income and middle-income countries regarding cervical cancer is expected to hinder growth of the generic oncology sterile injectables market during the forecast period. Cervical cancer is one of the most common cancers among women of reproductive age in low-income and middle-income countries. For instance, according to The International Agency for Research on Cancer's (IARC) report of 2013, cervical cancer is mostly prevalent in low-income countries of sub-Saharan Africa.
Key features of the study
- It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
- This study provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
- It profiles key players in the global generic oncology sterile injectable market based on the following parameters: company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
- Key players covered as a part of this study include Eli Lilly & Company, Biocon Ltd., Baxter International Inc., Hikma Pharmaceuticals PLC, Mylan N.V., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., and Pfizer Inc.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
- The global generic oncology sterile injectable market report caters to various stakeholders in this industry, which include investors, product manufacturers, distributors, and suppliers of generic oncology sterile injectable market, research and consulting firms, new entrants, and financial analysts.
Market Segmentation
- Global Generic Oncology Sterile Injectables Market, By Product Type
- Chemotherapy
- Alkylating agents
- Antimetabolites
- Plant Alkaloids
- Antitumor Antibiotics
- Others
- Monoclonal Antibodies
- Cytokines
- Peptide Hormones
- Global Generic Oncology Sterile Injectables Market, By Disease Indication
- Ovarian Cancer
- Breast Cancer
- Lung Cancer
- Pancreatic Cancer
- Others
- Global Generic Oncology Sterile Injectables Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Generic Oncology Sterile Injectables Market, By Region
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- North Africa
- Central Africa
- South Africa
- Key Players
- Eli Lilly & Company
- Biocon Ltd
- Baxter International Inc.
- Hikma Pharmaceuticals PLC
- Mylan N.V.
- Sandoz International GmbH
- Teva Pharmaceutical Industries Ltd
- Pfizer Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Overview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Product Type
- Market Snippet, By Disease Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Market Trends
- Key Developments
- Regulatory Scenario
- Industry Trend
- Merger and Acquisitions
- New Product Approvals/Launch
- Promotion and Marketing Initiatives
- PEST Analysis
4. Global Generic Oncology Sterile Injectables Market, By Product Type, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2021 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Alkylating agents
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Antimetabolites
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Plant Alkaloids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Antitumor Antibiotics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Cytokines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Peptide Hormones
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global Generic Oncology Sterile Injectables Market, By Disease Indication, 2021- 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2021 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Ovarian Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Pancreatic Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Generic Oncology Sterile Injectables Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2021 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Generic Oncology Sterile Injectables Market, By Region, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, By Region, 2021 and 2033 (%)
- Y-o-Y Growth Analysis, By Region, 2021 - 2026
- Regional Trends
- North America
- Market Size and Forecast, By Product Type, 2021 - 2033 , (USD Bn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- U.S.
- Canada
- Europe
- Market Size and Forecast, By Product Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Product Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Market Size and Forecast, By Product Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Middle East
- Market Size and Forecast, By Product Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Product Type, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Disease Indication, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, (USD Bn)
- North Africa
- Central Africa
- South Africa
8. Competitive Landscape
- Company Profiles
- Eli Lilly & Company
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Biocon Ltd
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Baxter International Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Hikma Pharmaceuticals PLC
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Mylan N.V.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Sandoz International GmbH
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Teva Pharmaceutical Industries Ltd
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Pfizer Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Analyst Views
- Eli Lilly & Company
9. Section
- References
- Research Methodology
- About Us and Sales Contact
